Gilead Sciences (NASDAQ:GILD) Issues Earnings Results

Gilead Sciences (NASDAQ:GILD) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.89 by $0.14, Zacks reports. The company had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.81 earnings per share. Gilead Sciences updated its FY 2026 guidance to -1.050–0.650 EPS.

Here are the key takeaways from Gilead Sciences’ conference call:

• Gilead raised 2026 revenue guidance by $400 million after a strong Q1, with updated 2026 base business sales of $29.4B–$29.8B and total product sales now expected at $30.0B–$30.4B, reflecting broad commercial execution.
• The U.S. PrEP franchise accelerated (PrEP sales +87% YoY) driven by YES2GO’s rapid launch (Q1 sequential growth +72%), and Gilead raised YES2GO 2026 guidance to ~$1 billion with ~95% U.S. coverage and high $0 copay access.
• Key HIV pipeline catalysts remain on track: the once-daily bictegravir+lenacapavir (BIC/LEN) is under priority FDA review with a decision expected in August, and multiple long-acting oral/injectable programs could support new launches through 2033.
• Gilead closed Arcellx and is acquiring Ouro Medicines and Tubulis, and upfront acquired IPR&D and transaction financing (~$11.5B in upfronts and ~$9.50/share impact) drive a 2026 non‑GAAP EPS range of $(1.05)–$(0.65) and an unusually high effective tax rate (140%–190%).
• Oncology and cell therapy momentum continued: Trodelvy sales were +37% YoY with potential first‑line metastatic TNBC regulatory decisions in H2 2026, and anito‑cel (Arcellx) has a December PDUFA with revenue expected to begin in early 2027.

Gilead Sciences Trading Down 1.6%

Shares of GILD traded down $2.24 during mid-day trading on Thursday, reaching $134.06. The stock had a trading volume of 8,889,606 shares, compared to its average volume of 5,546,303. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. Gilead Sciences has a 52-week low of $95.29 and a 52-week high of $157.29. The business’s fifty day moving average is $139.59 and its 200 day moving average is $132.87. The firm has a market cap of $166.40 billion, a price-to-earnings ratio of 19.80, a P/E/G ratio of 1.80 and a beta of 0.31.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat estimates — Gilead reported $2.03 EPS vs. a $1.89 consensus and revenue of $6.96B vs. ~$6.91B, showing underlying quarter strength. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 sales forecast, indicating revenue strength despite other headwinds. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Full‑year revenue guidance was issued at roughly $30.0–30.4B, near analyst consensus — so sales expectations are roughly intact even as profit guidance shifted. Gilead Press Release / Slide Deck
• Neutral Sentiment: Shareholders approved the board and executive pay plans at the 2026 meeting — governance items cleared without disruption. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Negative Sentiment: Company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share (versus prior ~$8.45–8.85 outlook and analyst expectations near $8.65), a dramatic revision that hits valuation and investor confidence. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
• Negative Sentiment: Management attributes the profit swing to acquisition‑related charges and financing costs tied to recent deals — these one‑time and financing items meaningfully depress reported earnings for the year. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Analysts Set New Price Targets

A number of research firms have recently issued reports on GILD. TD Cowen upped their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Scotiabank upped their target price on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a report on Wednesday, February 11th. The Goldman Sachs Group upped their target price on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Morgan Stanley upped their target price on shares of Gilead Sciences from $171.00 to $175.00 and gave the stock an “overweight” rating in a report on Tuesday, April 28th. Finally, Royal Bank Of Canada upped their target price on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a report on Tuesday, April 7th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $157.35.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the transaction, the chief executive officer owned 632,567 shares of the company’s stock, valued at $81,702,353.72. This represents a 1.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the transaction, the insider directly owned 128,779 shares in the company, valued at $18,152,687.84. The trade was a 2.28% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 63,000 shares of company stock valued at $9,238,250. 0.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Sivia Capital Partners LLC lifted its position in Gilead Sciences by 16.8% in the second quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares during the last quarter. Bison Wealth LLC acquired a new position in Gilead Sciences in the fourth quarter valued at about $215,000. Brighton Jones LLC lifted its position in Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after buying an additional 2,450 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Gilead Sciences by 135.3% in the third quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 410 shares during the last quarter. Finally, Binnacle Investments Inc lifted its position in Gilead Sciences by 14.3% in the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 88 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.